on JP Jenkins Ltd (isin : GB00BPLKLR77)
E-therapeutics Announces FY2023/24 Results and Pipeline Progress
London, UK, 6 June 2024 - e-therapeutics plc has released its audited financial results for the year ending 31 January 2024 and provided an update on its pipeline.
The company showed significant progress with positive preclinical proof-of-concept data for four GalOmic™ RNAi assets. CEO Ali Mortazavi highlighted continued advancements, including ETX-258 studies in heart failure and a new MASH program, ETX-394. These efforts validate their AI-enhanced R&D approach.
Key progress includes IND-enabling studies for ETX-312 targeting MASH, and advanced plans for ETX-258 and ETX-394. Operationally, the company expanded HepNet™ data, leveraged proprietary data, and made strategic hires.
e-therapeutics also raised £28.9 million in April 2024 and appointed Lord David Prior as Chair in May 2024. Financial highlights show a cash balance of £20.7 million, revenues of £0.3 million, and increased R&D spend leading to a loss of £11.2 million for the year.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all JP Jenkins Ltd news